Trial Profile
An Open-Label, Two-Part, Single-Dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of MK-3102 in Patients With Impaired Renal Function
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Omarigliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 27 Aug 2019 Results assessing population pharmacokinetic and pharmacodynamic model by using data from phase I, II and III studies including this study published in the British Journal of Clinical Pharmacology.
- 24 Apr 2012 Actual patients number is 49 as reported by ClinicalTrials.gov.
- 10 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.